公开(公告)号：EP3055323A2

公开(公告)日：2016-08-17

申请号：EP14784378.3

申请日：2014-10-13

申请人： Oxford University Innovation Limited ,  Academisch Ziekenhuis Leiden (also acting under the name of Leiden University Medical)

发明人： LONGLEY, Rhea ,  SALMAN, Ahmed ,  SPENCER, Alexandra ,  HILL, Adrian ,  JANSE, Chris ,  KHAN, Shahid

IPC分类号： C07K14/445 ,  A61K39/00 ,  A61K39/015

CPC分类号： A61K39/015 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/005 ,  C07K14/445 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10021 ,  C12N2710/10022 ,  C12N2710/10023 ,  C12N2710/10034 ,  C12N2710/10043 ,  C12N2710/24021 ,  C12N2710/24022 ,  C12N2710/24023 ,  C12N2710/24034 ,  C12N2710/24043 ,  Y02A50/412

摘要： The invention relates to an antigenic composition or vaccine comprising a viral vector, the viral vector comprising nucleic acid encoding Plasmodium protein PfLSA1, or a part or variant of Plasmodium protein PfLSA1; PfLSAP2, or a part or variant of Plasmodium protein PfLSAP2; PfUIS3, or a part or variant of Plasmodium protein PfUIS3; PfI0580c, or a part or variant of Plasmodium protein PfI0580c; and PfSPECT-1, or a part or variant of Plasmodium protein PfSPECT-1.

摘要翻译： 本发明涉及包含病毒载体的抗原组合物或疫苗，所述病毒载体包含编码疟原虫蛋白PfLSA1的核酸或疟原虫蛋白PfLSA1的部分或变体; PfLSAP2或疟原虫蛋白PfLSAP2的一部分或变体; PfUIS3或疟原虫蛋白PfUIS3的一部分或变体; PfI0580c，或疟原虫蛋白PfI0580c的一部分或变体; 和PfSPECT-1，或疟原虫蛋白PfSPECT-1的一部分或变体。

公开(公告)号：EP3325403A1

公开(公告)日：2018-05-30

申请号：EP16739473.3

申请日：2016-07-15

申请人： Academisch Ziekenhuis Leiden (also acting under the name of Leiden University Medical)

发明人： VAN LEEUWEN, Fijs Willem Bernhard ,  ROOD, Marcus Theodorus Maria

IPC分类号： B82Y5/00 ,  G01N33/532

CPC分类号： C12N5/0006 ,  A61K47/6901 ,  B82Y5/00 ,  G01N33/532 ,  G01N33/56966

摘要： The invention relates to the utilization of specific cell surface biomarkers (preferably cell specific receptors) to generate a reversible layer-by-layer scaffold for the functionalization of cells. The cells of the present invention can be used in a wide variety of distinct applications, including cellular targeting, imaging, drug delivery, purification, cell sensing, diagnosis and waste stream/body fluid purification.

公开(公告)号：EP3615062A1

公开(公告)日：2020-03-04

申请号：EP18721024.0

申请日：2018-04-25

申请人： Universiteit Leiden ,  Academisch Ziekenhuis Leiden (also acting under the name of Leiden University Medical)

发明人： FILIPPOV, Dmitri V. ,  GENTIAL, Geoffroy, P., P. ,  VAN DER MAREL, Gijsbert ,  OSSENDORP, Ferry

IPC分类号： A61K39/39 ,  A61K47/55 ,  C07K7/04 ,  C07K7/08

公开(公告)号：EP3405483A2

公开(公告)日：2018-11-28

申请号：EP17701674.8

申请日：2017-01-20

申请人： Academisch Ziekenhuis Leiden (also acting under the name of Leiden University Medical)

发明人： ROEP, Bart Otto ,  VAN LUMMEL, Menno ,  VAN VEELEN, Peter Antonis ,  ZALDUMBIDE, Arnaud

IPC分类号： C07K14/62 ,  A61K38/08 ,  A61K38/10 ,  A61K38/28 ,  C07K7/06 ,  C07K7/08

CPC分类号： C07K14/62 ,  A61K35/15 ,  A61K38/00 ,  C07K7/06 ,  C07K7/08 ,  C12N2510/00 ,  G01N33/50

摘要： The present invention relates to the identification of novel peptides derived from aberrant proteins involved in Type 1 Diabetes mellitus (T1D), also known as defective ribosomal products (DRiPs). In particular the invention relates to epitopes present in DRiPs of the human preproinsulin (PPI) mRNA, its representative peptides and the use thereof in diagnosis, prevention and/or treatment of T1D. Moreover, the inventions relate to antibodies and antisera against the identified epitopes and the use thereof in the diagnosis of T1D.